Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study

AIMS: The international IMPROVE™ observational study investigated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30) in the routine treatment of patients with type 2 diabetes. We present analyses for the subgroup of patients who switched from basal insulin to BIAsp 30....

Descripción completa

Detalles Bibliográficos
Autores principales: Gumprecht, J, Benroubi, M, Borzi, V, Kawamori, R, Shaban, J, Shah, S, Shestakova, M, Wenying, Y, Ligthelm, R, Valensi, P
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Late Breakers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734926/
https://www.ncbi.nlm.nih.gov/pubmed/19504715
http://dx.doi.org/10.1111/j.1742-1241.2009.02064.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734926/
https://www.ncbi.nlm.nih.gov/pubmed/19504715
http://dx.doi.org/10.1111/j.1742-1241.2009.02064.x

Ejemplares similares